Friday, August 13, 2021 5:08:09 PM
Recent PSTX News
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology • PR Newswire (US) • 05/02/2024 01:30:00 AM
- Biotech Soars on Research Collaboration And License Agreement Release • AllPennyStocks.com • 05/01/2024 07:25:00 PM
- Astellas and Poseida Therapeutics Enter Into Research Collaboration and License Agreement to Develop Novel Allogeneic Cell Therapies in Oncology • PR Newswire (US) • 05/01/2024 01:00:00 PM
- Poseida Therapeutics Announces Strong Lineup of Presentations at the American Society of Gene and Cell Therapy 27th Annual Meeting • PR Newswire (US) • 04/18/2024 12:00:00 PM
- Poseida Therapeutics Hosts Gene Therapy R&D Day Highlighting New Scientific Advancements and Pipeline Focus • PR Newswire (US) • 04/17/2024 01:00:00 PM
- Poseida Therapeutics Presents New Phase 1 Data at AACR 2024 Supporting Potential of P-BCMA-ALLO1 Allogeneic CAR-T Therapy to Benefit Broad Range of Patients with Multiple Myeloma • PR Newswire (US) • 04/08/2024 04:00:00 PM
- Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 04/01/2024 08:05:00 PM
- Poseida Therapeutics Appoints Syed Rizvi, M.D., as Chief Medical Officer • PR Newswire (US) • 03/25/2024 08:05:00 PM
- Poseida Therapeutics to Present at H.C. Wainwright 2nd Annual Cell Therapy Virtual Conference • PR Newswire (US) • 03/19/2024 08:05:00 PM
- Poseida Therapeutics Announces FDA Orphan Drug Designation Granted to P-BCMA-ALLO1 for the Treatment of Multiple Myeloma • PR Newswire (US) • 03/13/2024 08:05:00 PM
- Poseida Therapeutics Provides Updates and Financial Results for the Fourth Quarter and Full Year 2023 • PR Newswire (US) • 03/07/2024 09:07:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/07/2024 09:05:52 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:29:56 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/04/2024 10:18:30 PM
- Poseida Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) • PR Newswire (US) • 03/04/2024 09:05:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/08/2024 09:10:02 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 01/04/2024 09:03:48 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 09:01:31 PM
- Poseida Therapeutics Highlights Recent Progress, Strategic Priorities and Anticipated 2024 Key Milestones • PR Newswire (US) • 01/04/2024 01:00:00 PM
- Poseida Therapeutics Shares Climb on Positive Data for Blood Cancer Treatment • Dow Jones News • 12/11/2023 03:31:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/11/2023 11:06:31 AM
- Poseida Therapeutics Presents Positive Early Results from its Phase 1 Trial of Allogeneic CAR-T P-BCMA-ALLO1 in Relapsed-Refractory Multiple Myeloma at the 65th American Society of Hematology (ASH) Annual Meeting • PR Newswire (US) • 12/10/2023 05:00:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/09/2023 09:11:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/09/2023 09:05:53 PM
- Poseida Therapeutics Provides Updates and Financial Results for the Third Quarter of 2023 • PR Newswire (US) • 11/09/2023 09:05:00 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM